Literature DB >> 17204705

Human biodistribution and radiation dosimetry of the tachykinin NK1 antagonist radioligand [18F]SPA-RQ: comparison of thin-slice, bisected, and 2-dimensional planar image analysis.

David R Sprague1, Frederick T Chin, Jeih-San Liow, Masahiro Fujita, H Donald Burns, Richard Hargreaves, James B Stubbs, Victor W Pike, Robert B Innis, P David Mozley.   

Abstract

UNLABELLED: (18)F-Labeled substance P antagonist-receptor quantifier ([(18)F]SPA-RQ) [2-fluoromethoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzyl]-[(2S,3S)-2-phenyl-piperidin-3-yl)amine] is a selective radioligand for in vivo quantification of tachykinin NK(1) receptors with PET. The aims of this study were to estimate the radiation safety profile and relative risks of [(18)F]SPA-RQ with 3 different methods of image analysis.
METHODS: Whole-body PET images were acquired in 7 healthy subjects after injection of 192 +/- 7 MBq (5.2 +/- 0.2 mCi) [(18)F]SPA-RQ. Emission images were serially acquired at multiple time-points from 0 to 120 min and approximately 180-240 min after injection. Urine samples were collected after each imaging session and for 24 h after the last scan to measure excreted radioactivity. Horizontal tomographic images were compressed to varying degrees in the anteroposterior direction to create 3 datasets: thin-slice, bisected, and 2-dimensional (2D) planar images. Regions of interest were drawn around visually identifiable source organs to generate time-activity curves for each dataset. Residence times were determined from these curves, and doses to individual organs and the body as a whole were calculated using OLINDA/EXM 1.0.
RESULTS: The lungs, upper large intestine wall, small intestine, urinary bladder wall, kidneys, and thyroid had the highest radiation-absorbed doses. Biexponential fitting of mean bladder and urine activity showed that about 41% of injected activity was excreted via urine. Assuming a 2.4-h urine voiding interval, the calculated effective doses from thin-slice, bisected, and 2D planar images were 29.5, 29.3, and 32.3 microSv/MBq (109, 108, and 120 mrem/mCi), respectively.
CONCLUSION: Insofar as effective dose is an accurate measure of radiation risk, all 3 methods of analysis provided quite similar estimates of risk to human subjects. The radiation dose was moderate and would potentially allow subjects to receive multiple PET scans in a single year. Individual organ exposures varied among the 3 methods, especially for structures asymmetrically located in an anterior or posterior position. Bisected and 2D planar images almost always provided higher organ dose estimates than thin-slice images. Thus, either the bisected or 2D planar method of analysis appears acceptable for quantifying human radiation burden, at least for radioligands with a relatively broad distribution in the body and not concentrated in a small number of radiation sensitive organs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17204705      PMCID: PMC4135382     

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  23 in total

1.  Synthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK1 receptor quantitation: ([18F]SPA-RQ).

Authors:  Olof Solin; Olli Eskola; Terence G Hamill; Jörgen Bergman; Pertti Lehikoinen; Tove Grönroos; Sarita Forsback; Merja Haaparanta; Tapio Viljanen; Christine Ryan; Raymond Gibson; Gerard Kieczykowski; Jarmo Hietala; Richard Hargreaves; H Donald Burns
Journal:  Mol Imaging Biol       Date:  2004 Nov-Dec       Impact factor: 3.488

2.  Biodistribution and radiation dosimetry of 18F-fluoro-A-85380 in healthy volunteers.

Authors:  Michel Bottlaender; Héric Valette; Dimitri Roumenov; Frédéric Dollé; Christine Coulon; Michèle Ottaviani; Françoise Hinnen; Marcel Ricard
Journal:  J Nucl Med       Date:  2003-04       Impact factor: 10.057

3.  Whole-body biodistribution, radiation dosimetry estimates for the PET norepinephrine transporter probe (S,S)-[18F]FMeNER-D2 in non-human primates.

Authors:  Nicholas Seneca; Bengt Andree; Nils Sjoholm; Magnus Schou; Stefan Pauli; P David Mozley; James B Stubbs; Jeih-San Liow; Judit Sovago; Balazs Gulyás; Robert Innis; Christer Halldin
Journal:  Nucl Med Commun       Date:  2005-08       Impact factor: 1.690

4.  Increased tachykinin NK(1) receptor immunoreactivity in the prefrontal cortex in schizophrenia.

Authors:  P A Tooney; V C Crawter; L A Chahl
Journal:  Biol Psychiatry       Date:  2001-03-15       Impact factor: 13.382

5.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.

Authors:  Michael G Stabin; Richard B Sparks; Eric Crowe
Journal:  J Nucl Med       Date:  2005-06       Impact factor: 10.057

6.  Substance P immunoreactivity in Rett syndrome.

Authors:  K Deguchi; B A Antalffy; L J Twohill; S Chakraborty; D G Glaze; D D Armstrong
Journal:  Pediatr Neurol       Date:  2000-04       Impact factor: 3.372

Review 7.  Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.

Authors:  Kelly Pendergrass; Richard Hargreaves; Kevin J Petty; Alexandra D Carides; Judith K Evans; Kevin J Horgan
Journal:  Drugs Today (Barc)       Date:  2004-10       Impact factor: 2.245

8.  Radiation dosimetry estimates for the PET serotonin transporter probe 11C-DASB determined from whole-body imaging in non-human primates.

Authors:  D N Tipre; J Q Lu; M Fujita; M Ichise; D Vines; R B Innis
Journal:  Nucl Med Commun       Date:  2004-01       Impact factor: 1.690

Review 9.  Imaging substance P receptors (NK1) in the living human brain using positron emission tomography.

Authors:  Richard Hargreaves
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

10.  Neurokinin-1 receptors are decreased in major depressive disorder.

Authors:  Craig A Stockmeier; Xiaochun Shi; Lisa Konick; James C Overholser; George Jurjus; Herbert Y Meltzer; Lee Friedman; Pierre Blier; Grazyna Rajkowska
Journal:  Neuroreport       Date:  2002-07-02       Impact factor: 1.837

View more
  11 in total

1.  Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography.

Authors:  Garth E Terry; Jussi Hirvonen; Jeih-San Liow; Nicholas Seneca; Johannes T Tauscher; John M Schaus; Lee Phebus; Christian C Felder; Cheryl L Morse; Victor W Pike; Christer Halldin; Robert B Innis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-24       Impact factor: 9.236

Review 2.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

3.  Biodistribution and radiation dosimetry of a positron emission tomographic ligand, 18F-SP203, to image metabotropic glutamate subtype 5 receptors in humans.

Authors:  Yasuyuki Kimura; Fabrice G Siméon; Jun Hatazawa; P David Mozley; Victor W Pike; Robert B Innis; Masahiro Fujita
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-29       Impact factor: 9.236

4.  Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral pain.

Authors:  Johanna M Jarcho; Natasha A Feier; Alberto Bert; Jennifer A Labus; Maunoo Lee; Jean Stains; Bahar Ebrat; Stephanie M Groman; Kirsten Tillisch; Arthur L Brody; Edythe D London; Mark A Mandelkern; Emeran A Mayer
Journal:  Pain       Date:  2013-03-05       Impact factor: 6.961

5.  Kinetic brain analysis and whole-body imaging in monkey of [11C]MNPA: a dopamine agonist radioligand.

Authors:  Nicholas Seneca; Mette Skinbjerg; Sami S Zoghbi; Jeih-San Liow; Robert L Gladding; Jinsoo Hong; Pavitra Kannan; Edward Tuan; David R Sibley; Christer Halldin; Victor W Pike; Robert B Innis
Journal:  Synapse       Date:  2008-09       Impact factor: 2.562

6.  The clinical safety, biodistribution and internal radiation dosimetry of [¹⁸F]fluciclovine in healthy adult volunteers.

Authors:  Brian J McParland; Anders Wall; Silvia Johansson; Jens Sørensen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-24       Impact factor: 9.236

7.  Human biodistribution and radiation dosimetry of 11C-(R)-PK11195, the prototypic PET ligand to image inflammation.

Authors:  Jussi Hirvonen; Anne Roivainen; Jere Virta; Semi Helin; Kjell Någren; Juha O Rinne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-28       Impact factor: 9.236

8.  Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein.

Authors:  Nicholas Seneca; Sami S Zoghbi; Jeih-San Liow; William Kreisl; Peter Herscovitch; Kimberly Jenko; Robert L Gladding; Andrew Taku; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2009-04-16       Impact factor: 10.057

9.  Whole-body biodistribution and radiation dosimetry in monkeys and humans of the phosphodiesterase 4 radioligand [(11)C](R)-rolipram: comparison of two-dimensional planar, bisected and quadrisected image analyses.

Authors:  David R Sprague; Masahiro Fujita; Yong Hoon Ryu; Jeih-San Liow; Victor W Pike; Robert B Innis
Journal:  Nucl Med Biol       Date:  2008-05       Impact factor: 2.408

Review 10.  Molecular imaging of the pulmonary circulation in health and disease.

Authors:  Jocelyn Dupuis; François Harel; Quang T Nguyen
Journal:  Clin Transl Imaging       Date:  2014-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.